Clinical Trial Update: IV Busulfan Plus Bortezomib Conditioning Regimen for Second Autologous Stem Cell Transplant in Multiple Myeloma Patients [Phase 2]

View source ↗

Summary

Phase 2 results update for IV busulfan plus bortezomib conditioning before a second autologous stem cell transplant in multiple myeloma patients. Results were p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• BUSULFAN (Busulfan)
• Bortezomib (bortezomib)

Snippet

Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. | Conditions: Multiple Myeloma | Phase 2 | Status: COMPLETED | Results posted: 2014-08-07